Mirum Pharmaceuticals

MIRM

----

Q2 FY2026 EarningsQ2 FY2026 beat consensus on the top line with revenue of $176.2M vs. $166.4M expected, driven by 46% YoY growth in LIVMARLI sales. However, EPS of -$1.06 significantly missed the -$0.74 consensus due to higher-than-anticipated operating expenses, including a $16.4M non-recurring IPR&D charge. Positive commercial momentum led management to raise FY2026 product sales guidance to $680M-$700M, though the volixibat NDA for PSC is now delayed to H1 2027.

Financial report interval: 2026.03.30 - 2026.06.30

Overview: Mirum Pharmaceuticals(MIRM) the Revenue is 176.24 M (+37.92%), Beat estimate;the EBIT is -42.54 M (-752.6%), Miss estimate;the EPS is -1.06 (-783.3%), Miss estimate.

Actual

YoY

Estimate

YoY

Vs estimate

YoY

RevenueExceed expectations

0.18B37.92%

0.17B30.20%

+0.01B7.72%

EBITMiss expectations

-0.04B752.62%

-0.04B645.61%

-0.01B107.01%

EPSMiss expectations

-1.06783.33%

-0.7431519.28%

-0.3169264.05%

Upcoming earnings report - Q3 FY2026

Available dateNov 2, 2026

Estimate Revenue$178.06 M

Estimate EBIT-$30.5 M

Estimate EPS-$0.4892

Revenue

ActualEstimateUnit: USD

Quarterly

EBIT

ActualEstimateUnit: USD

Quarterly

Net income

ActualEstimateUnit: USD

Quarterly

EPS

ActualEstimateUnit: USD

Quarterly